BioMedNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) CEO Discusses ‘Sea of Change’ to Future of Anxiety Treatment

VistaGen Therapeutics’ (NASDAQ: VTGN) CEO Shawn Singh authored a recent article for Life Science Leader titled, “The Future of Anxiety Treatment Will Be Drastically Different.” In the piece, Singh, an experienced professional who has dedicated over 25 years to biopharma and medical device industries, addresses the current standard of care for anxiety disorders and its inability to meet the growing need. “As researchers learn more about psychological therapy for anxiety disorders and medication options to complement it, efforts are underway to develop innovative medications to displace current anti-anxiety drugs that are not effective for all patients and are associated with significant potential side effects and safety concerns, especially benzodiazepines,” Singh writes. “If these new generation alternatives are developed successfully in adequate and well-controlled clinical trials, the future of anxiety disorder treatment will look drastically different from the current standard of care, and that sea of change couldn’t come a moment too soon.”

Click here to view the full article

About VistaGen Therapeutics

VistaGen is a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other CNS disorders where the current standard of care is inadequate, resulting in high unmet need. Each of VistaGen’s three drug candidates has a differentiated mechanism of action, an exceptional safety profile in all studies to date, and therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork